Trial Profile

Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Multiple sclerosis vaccine (Primary)
Indications Multiple sclerosis
Focus First in man; Proof of concept; Therapeutic Use

Most Recent Events

01 Apr 2016 Results published in a PJSC Pharmsynthez media release.
01 Apr 2016 Status changed from active, no longer recruiting to completed, according to a PJSC Pharmsynthez media release.
21 Nov 2014 Dosing of patients completed, according to a Xenetic Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com